How to achieve international action on falsified and substandard medicines A Attaran, D Barry, S Basheer, R Bate, D Benton, J Chauvin, L Garrett, ... Bmj 345, 2012 | 197 | 2012 |
Medical certification of cause of death: instructions for physicians on use of international form of medical certificate of cause of death World Health Organization World Health Organization, 1979 | 190* | 1979 |
The sustainable development goals as a framework to combat health-sector corruption TK Mackey, T Vian, J Kohler Bulletin of the World Health Organization 96 (9), 634, 2018 | 111 | 2018 |
Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers HA Garuba, JC Kohler, AM Huisman Globalization and health 5, 1-13, 2009 | 104 | 2009 |
The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk JC Kohler, D Dimancesco Global health action 13 (sup1), 1694745, 2020 | 101 | 2020 |
Benchmarking and transparency: Incentives for the pharmaceutical industry’s corporate social responsibility M Lee, J Kohler Journal of Business Ethics 95, 641-658, 2010 | 92 | 2010 |
Social capital and public health: responding to the COVID-19 pandemic ASY Wong, JC Kohler Globalization and health 16 (1), 88, 2020 | 91 | 2020 |
The disease of corruption: views on how to fight corruption to advance 21st century global health goals TK Mackey, JC Kohler, WD Savedoff, F Vogl, M Lewis, J Sale, J Michaud, ... BMC medicine 14, 1-16, 2016 | 86 | 2016 |
The role of supportive supervision on immunization program outcome-a randomized field trial from Georgia M Djibuti, G Gotsadze, A Zoidze, G Mataradze, LC Esmail, JC Kohler BMC international health and human rights 9, 1-12, 2009 | 81 | 2009 |
Orphan drug policies: implications for the United States, Canada, and developing countries RY Cheung, JC Cohen, P Illingworth Health LJ 12, 183, 2004 | 77 | 2004 |
Global health and human rights in the time of COVID-19: Response, restrictions, and legitimacy L Forman, JC Kohler Rights at Stake and the COVID-19 Pandemic, 33-42, 2023 | 75 | 2023 |
Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance T Vian, JC Kohler, G Forte, D Dimancesco Journal of Pharmaceutical Policy and Practice 10, 1-11, 2017 | 74 | 2017 |
AIDS policy and pharmaceutical patents: Brazil's strategy to safeguard public health JC Cohen, KM Lybecker World Economy 28 (2), 211-230, 2005 | 68 | 2005 |
The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements JC Cohen, P Illingworth Developing world bioethics 3 (1), 27-48, 2003 | 67 | 2003 |
The morally uncomfortable global drug gap JC Cohen‐Kohler Clinical Pharmacology & Therapeutics 82 (5), 610-614, 2007 | 65 | 2007 |
Corruption and pharmaceuticals: Strengthening good governance to improve access JC Cohen, MF Mrazek, L Hawkins The Many Faces of Corruption: Tracking Vulnerabilities at the Sector Level …, 2007 | 65 | 2007 |
Increasing transparency and accountability in national pharmaceutical systems A Paschke, D Dimancesco, T Vian, JC Kohler, G Forte Bulletin of the World Health Organization 96 (11), 782, 2018 | 63 | 2018 |
Corruption in the health care sector: A barrier to access of orthopaedic care and medical devices in Uganda M Bouchard, JC Kohler, J Orbinski, A Howard BMC international health and human rights 12, 1-9, 2012 | 59 | 2012 |
Tackling corruption in the pharmaceutical systems worldwide with courage and conviction JC Cohen, M Mrazek, L Hawkins Clinical Pharmacology & Therapeutics 81 (3), 445-449, 2007 | 57 | 2007 |
Pharmaceuticals and corruption: a risk assessment JC Cohen Global corruption report 2006, 77-84, 2006 | 56 | 2006 |